Almotriptan

A triptan (serotonin 5-HT1B/1D agonist), FDA-approved for acute treatment of migraine in adults and adolescents 12 to 17.

psilodex.org/m/almotriptan · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: 3–4 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Almotriptan”, v2026.10.05. psilodex.org/m/almotriptan

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Generic only in US

FDA-approved for

Migraine attacks (acute treatment, adults)
Migraine headache pain in adolescents 12 to 17 (acute treatment)

Sources [1]

Other safety

Contraindicated in ischemic heart disease, coronary vasospasm, stroke or TIA history, peripheral vascular disease, uncontrolled hypertension, hemiplegic or basilar migraine, and within 24 hours of another triptan or an ergot-type drug.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

It may add to psilocybin's serotonin activity and brief blood pressure rise. Also, its label reports rare significant blood pressure elevation.

Detail Almotriptan is a triptan (a 5-HT1B/1D agonist) that narrows blood vessels. It may add to psilocybin's serotonergic effects and brief blood pressure rise; it has not been studied with psilocybin. It is metabolized by MAO-A, CYP3A4 and CYP2D6, liver enzymes that also metabolized psilocin in lab studies. Also, its label reports serotonin syndrome with SSRIs and SNRIs, and rare significant blood pressure elevation. Sources [1][2]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: 3–4 h (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]
Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

ALMOTRIPTAN tablet, film coated (Ajanta) · FDA label (DailyMed) — revised 2026-01 | Serotonergic: 5.5 Serotonin Syndrome "The development of a potentially life-threatening serotonin syndrome may occur with triptans, including almotriptan tablets, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)." | Raises blood pressure or heart rate: 5.7 Increases in Blood Pressure "As with other triptans, significant elevations in systemic blood pressure have been reported on rare occasions with almotriptan tablets use in patients with and without a history of hypertension" | 12.3 Pharmacokinetics "MAO-A is responsible for the formation of the indoleacetic acid metabolite, whereas cytochrome P450 (3A4 and 2D6) catalyzes the hydroxylation of the pyrrolidine ring" | 12.3 Pharmacokinetics "Almotriptan has a mean half-life of 3 to 4 hours."
Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. — Lab studies: MAO-A, CYP2D6 and CYP3A4 metabolized psilocin; glucuronidation and conversion to 4-HIAA are the main routes.

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →